Detecting functional changes with [18F]FAZA in a renal cell carcinoma mouse model following sunitinib therapy by David W Chapman et al.
Chapman et al. EJNMMI Research 2014, 4:27
http://www.ejnmmires.com/content/4/1/27ORIGINAL RESEARCH Open AccessDetecting functional changes with [18F]FAZA in a
renal cell carcinoma mouse model following
sunitinib therapy
David W Chapman1,2, Hans-Sonke Jans1, Ivy Ma2, John R Mercer1, Leonard I Wiebe1, Melinda Wuest1*†
and Ronald B Moore1,2†Abstract
Background: The multitargeting tyrosine kinase inhibitor (TKI) sunitinib is currently the first-line drug therapy for
metastasizing renal cell carcinoma (RCC). TKIs have profound effects on tumor angiogenesis, leading to modifications
of the tumor microenvironment. The goal of this study was to determine whether these treatment-induced changes
can be detected with [18F]FAZA.
Methods: The present study utilized positron emission tomography (PET) to analyze tumor oxygenation status during
and after sunitinib therapy in the murine Caki-1 RCC tumor model. Dynamic and static scans were performed, as well
as ex vivo biodistributions at 3 h post injection (p.i.). Immunohistochemical analysis of tumor tissue was carried out for
the quantification of pimonidazole binding and the hypoxia-associated factors CD-31, Ki-67, and Von Willebrand factor
(VWF). In addition, in vitro cellular uptake studies were done to analyze the direct effects of sunitinib on the Caki-1 cells.
Results: During therapy with sunitinib (40 mg/kg/day), uptake of [18F]FAZA into Caki-1 mice decreased by 46 ± 5%
(n = 4; 5 days) at 3 h post injection (p.i.) during the first study and 22 ± 5% (n = 8; 9 days) during the long-term study,
indicating a decrease in the tumor's hypoxia level. However, when drug therapy was stopped, this effect was reversed
completely, and the tumor [18F]FAZA uptake increased to 126 ± 6% (n = 6) of the control tumor uptake, indicative of an
even higher level of tumor hypoxia compared to the therapy starting point. Sunitinib had no direct effect on [18F]FAZA
uptake into Caki-1 cells in vitro.
Conclusion: [18F]FAZA PET could be used to monitor drug response during sunitinib therapy in RCC and may guide
combination therapies based on the tumor's hypoxia status.
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Renal cell carcinoma (RCC) is the third most diagnosed
urological malignancy, with 75% of cases being the clear
cell RCC histological subtype [1]. RCC arises in the prox-
imal tubule of the nephron within the kidney; its symp-
toms present late, often preventing diagnosis early enough
to lead to a favorable prognosis [2]. The American Cancer
Society estimated 65,150 new cases and 13,680 deaths in
the USA in 2013, a significant increase compared to the* Correspondence: mwuest@ualberta.ca
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in any medium, provided the original work is p2005 prediction statistics of 36,160 new cases and 12,660
deaths [3,4]. Between 2005 and 2009, the overall inci-
dence of kidney cancer in the USA increased 3.1% per
year [3], which is comparable to the observed 2% increase
over the past two decades worldwide and within Europe
[5]. Barring early intervention, many patients will experi-
ence metastatic disease and require systemic therapy.
Metastatic RCC (mRCC) rarely shows a complete and dur-
able response to immuno- or radiation therapy [6]. Signifi-
cant improvements in patient management have been
achieved, however, with the development of targeted small
molecules including tyrosine kinase inhibitors (TKIs)
such as sunitinib, sorafenib, pazopanib, and axitinib [7-9].
Two types of TKIs are known to date. Termed type I andis an Open Access article distributed under the terms of the Creative Commons
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binding site of the tyrosine kinase [10]. Sunitinib repre-
sents a TKI of type I, which targets mainly the vascular
endothelial growth factor receptor 2 (VEGFR 2) and the
platelet-derived growth factor receptors (PDGFR) α and β,
the stem cell growth factor c-KIT (CD117), the RET proto-
oncogene, and the Fms-like tyrosine kinase 3 (FLT-3). In
addition, sunitinib has also been shown to inhibit 72 other
kinases [11,12], justifying its classification as a multitarget-
ing receptor kinase inhibitor [13,14]. Sunitinib is currently
approved for the treatment of gastrointestinal stromal tu-
mors (GIST), pancreatic neuroendocrine tumors, and as
first-line therapy for mRCC [15,16].
Sunitinib not only acts directly on tumors cells (GIST
and RCC) but also indirectly by disrupting the develop-
ment of blood vessels, leading to increased microenvi-
ronmental stress on the tumor tissue [12]. A number of
receptor tyrosine kinases are controlled by multikinase
inhibitors such as sunitinib and sorafenib. They modu-
late hypoxia-inducible factor 1α (HIF-1α), indicating that
antiangiogenic effects might be achieved not only by dir-
ect action on vascular endothelial cells but also by block-
ing compensatory hypoxia- and ligand-induced changes in
HIF-1α and HIF-2α expression in the target tumor cells
[17]. HIF-1α levels are controlled by the oxygen tension
within a cell. Under hypoxic conditions, HIF-1α is acti-
vated and, in turn, triggers the production of proteins such
as VEGF, PDGF, TGF, EGF, GLUT1 and CA IX, which are
all essential for angiogenesis [18,19].
Positron emission tomography (PET), a non-invasive im-
aging method, is a tool well suited for in vivo detection
and characterization of hypoxia in a tumor's microenviron-
ment [20,21]. As a clinical tool, PET can be helpful in the
diagnosis, outcome prediction, and therapy monitoring of
RCC cancer patients [22]. Its broader clinical utilization in
this context is, however, subject to discussion [23]. Several
PET radiotracers for the imaging of tumor hypoxia have
been developed, such as the 2-nitroimidazoles [18F]FMISO,
[18F]FAZA, [18F]EF5, and the copper-64-based thiosemi-
carbazone [64Cu]ATSM [24,25]. Among them, [18F]FMISO
is the most extensively studied and widely used PET radio-
tracer for quantitative assessment of tumor hypoxia in
both preclinical and clinical settings [21]. [18F]FAZA and
[64Cu]ATSM may also be useful, depending on the pa-
tient cohort. [18F]FAZA, because of its lower lipophy-
licity and therefore faster blood and non-target tissue
clearance, exhibits superior image contrast [26]. [18F]FAZA
and [18F]FMISO yield tumor-to-kidney ratios that are
similar to each other and larger when compared to [64Cu]
ATSM [27-29]. At present, it is unknown which hypoxia
PET radiotracer would provide the greatest tumor-to-
background ratio in RCC patients.
PET radiotracers were used in several clinical and nu-
merous preclinical studies to detect tumor hypoxia andpredict and analyze tumor response to chemotherapy.
These tracers may play a role in guiding hypoxia-specific
treatment in cancer patients [30]. Most commonly, [18F]
FMISO and [18F]FDG were used to detect effects of a
therapy with TKIs such as sunitinib or sorafenib [31-36].
To date, only one preclinical study was performed using
[18F]FAZA [37]. Here, the effects of gefitinib, an epidermal
growth factor receptor (EGFR) inhibitor, were monitored.
The current study utilizes [18F]FAZA to detect functional
changes in the microenvironment of a renal cell carcin-
oma mouse model during sunitinib therapy and subse-
quent withdrawal. It is known that a TKI therapy regimen,
which is typically split into therapeutic fractions, induces a
withdrawal flare phenomenon in RCC patients [38,39].
The goal of this study was to determine whether these
treatment-induced changes in tumor hypoxia can be de-
tected and quantified using a PET radiotracer for hypoxia
in an animal model. This ability could help optimize the
timing of combination therapy in metastatic RCC patients.
[18F]FAZA has been chosen because of its lower lipophyli-
city and elevated clearance.
Methods
Animal model
All animal experiments were carried out in compliance with
the guidelines of the Canadian Council on Animal Care and
with approval from the local Animal Care Committee of
the Cross Cancer Institute under the protocol number
AC 11183. Caki-1 is a human epithelial kidney clear cell
carcinoma cell line which expresses the wild-type von
Hippel-Lindau tumor suppressor protein and was derived
from a metastatic site. Donor tumors in mice were gener-
ated by injecting approximately 100,000 Caki-1 tumor
cells subcutaneously into a BALB/c nude mouse (Charles
River Laboratories, Quebec, Canada). Once the tumors
reached a suitable size of 400 to 500 mm3, they were frag-
mented into roughly equal size of 2 × 2-mm tissue chunks
and implanted into the left and right flanks of the experi-
mental BALB/c nude mice. The tumors became palpable
after 5 days, and when they reached an appropriate size
of 5 to 10 mm in diameter, they were randomly assigned
to the experimental groups: one receiving sunitinib ther-
apy, the other a control group receiving vehicle injec-
tions only. Three experimental setups were performed:
(A) short-term effects of sunitinib (5 days of therapy) on
tumor oxygenation, (B) long-term sunitinib therapy (14 days
of therapy; 5 days on, 2 days off), and (C) treatment with-
drawal (another 12 days after finishing therapy). After 4, 9,
and 14 days of treatment, as well as the 12 days after treat-
ment withdrawal, selected mice from both groups were
analyzed with PET. Sunitinib malate (Sutent™) was a
gift from Pfizer Canada (Kirkland, Quebec, Canada).
The mice in the treatment groups received intraperi-
toneal injection of 40 mg/kg/day of sunitinib malate
Chapman et al. EJNMMI Research 2014, 4:27 Page 3 of 11
http://www.ejnmmires.com/content/4/1/27in saline/1%DMSO; the control groups received vehicle
injections (saline/1%DMSO).
Positron emission tomography
PET detection of tumor hypoxia was performed on BALB/
c nude mice bearing subcutaneous Caki-1 tumors follow-
ing the injection of 1-(5-deoxy-5-[18F]fluoro-α-D-arabino-
furanosyl)-2-nitroimidazole ([18F]FAZA). Radiosynthesis of
[18F]FAZA was performed in automated synthesis units
according to a standard literature procedure [40]. The pre-
cursor for the [18F]FAZA synthesis, 1-(2,3-diacetyl-5-tosyl-
(α-D-arabinofuranosyl)-2-nitroimidazole, was purchased
from ABX GmbH (Radeberg, Germany). For PET experi-
ments, a catheter was placed into the tail vein of the se-
dated mouse. Under inhalation anesthesia, the mice were
placed in prone position with their medial axis parallel to
the axis of the microPET® R4 scanner (Siemens Preclinical
Solutions, Knoxville, TN, USA) and their thorax, ab-
domen, and hind legs centered in the field of view. A
transmission scan for attenuation correction was not
acquired. [18F]FAZA (4 to 5 MBq in 100- to 150-μL
solution - H2O/max. 8% EtOH and diluted with nor-
mal saline (NS)) was injected intravenously through the
catheter into the tail vein. For the different experimental
protocols, an emission scan of either 180-min (dy-
namic experiments in setup A) or 10-min (static scans in
setup B) PET acquisitions was subsequently performed.
The dynamic list mode data were sorted into sinograms
with 65 time frames (10 × 2, 8 × 5, 6 × 10, 6 × 20, 8 × 60,
10 × 120, 5 × 300, and 12 × 600 s). The frames were recon-
structed using ordered subset expectation maximization
(OSEM) or maximum a posteriori (MAP) reconstruction
modes. The pixel size was 0.085 × 0.085 × 0.12 cm, and
the resolution in the center field of view was 1.8 mm. Cor-
rection for partial volume effects was not performed. The
image files were further processed using the ROVER
v2.0.51 software (ABX GmbH). Masks defining 3D regions
of interest (ROI) were set, and the ROIs were defined by
thresholding. ROIs covered all visible tumor mass of the
subcutaneous tumors, and the thresholds were defined by
50% of the maximum radioactivity uptake level of each
Caki-1 tumor in each animal. Mean standardized uptake
values (SUVmean = (activity/mL tissue)/(injected activity/
body weight), mL/g) were calculated for each ROI. For
comparison, SUVmax was also analyzed for the static PET
experiments. Time-activity curves (TAC) were generated
for the dynamic scans only. All semi-quantified PET data
are presented as means ± SEM.
After each PET scan, the mice were immediately sacri-
ficed by cervical dislocation, and the tumors and muscle
tissue were collected in scintillation vials, weighed, and
counted using a Wizard-3 1480 automatic gamma counter
(Perkin-Elmer Life Sciences, Woodbridge, ON, Canada).
Biodistribution experimental results were analyzed aspercentage of injected dose per gram of tissue (%ID/g) or
as SUV. All biodistribution values were obtained at 3 h
post injection (p.i.) of the radiotracer. Data are presented
as means ± SEM.
Kinetic modeling
Based on investigations by Verwer et al. [41], a reversible
two-tissue compartment model with blood volume par-
ameter was applied to the data sets. For this purpose, an
ROI defining the heart content was generated by thresh-
olding the averaged early time frames which visualized
the blood flow through the heart. The plasma input
TAC generated from this ROI was convolved with the
compartmental model and numerically fitted to the tumor
TACs of the same animal. This procedure was imple-
mented in Matlab software (version R2014a), utilizing a
Nelder-Mead simplex direct search. The fit was governed
by the minimization of the sum over all time points of
square differences between the measured values and the
model prediction.
Immunohistochemistry
Following euthanization, the tumor tissue samples were col-
lected for preparation of formalin-fixed paraffin-embedded
tissue slides. One hour (short-term experiment with 5-day
sunitinib treatment only) or 3 h (long-term experi-
ment with 14 days of sunitinib therapy plus therapy with-
drawal) prior to sacrificing the animal, pimonidazole HCl
(Hypoxyprobe, Inc., Burlington, MA, USA) was injected
intraperitoneally at a dose of 60 mg/kg. Additionally, im-
munostaining for platelet endothelial cell adhesion mol-
ecule (PECAM) CD-31 (rabbit polyclonal anti-mouse
CD-31, Santa Cruz Biotechnology Inc., Dallas, TX, USA),
Von Willebrand factor (rabbit polyclonal von Willebrand
factor antibody), and Ki67 (rabbit monoclonal anti-mouse
Ki67, Abcam Inc., Toronto, ON, Canada) were performed
to illustrate changes in neoangiogenesis and vascular dens-
ity. Briefly, following rehydration and antigen retrieval, en-
dogenous peroxidase activity was blocked using methanol
containing 0.3% hydrogen peroxide. After that, the sec-
tions were incubated for 1 h with the subsequent primary
monoclonal antibody. The bound antibodies were visual-
ized using DakoCyomation Envision-horseradish peroxid-
ase and chromagen using the EnVision™ FLEX kit (Dako
Canada, Burlington, Ontario, Canada). The slides were
counterstained with hemotoxylin and analyzed under a
microscope (Axiocam HR, Zeiss, Oberkochen, Germany).
The images were edited with Adobe® Photoshop (Adobe
Systems Inc., San Jose, CA, USA) to remove connective
and non-tumor tissue surrounding the tumor. Then, using
MetaMorph® Microscopy Automation & Image Analysis
Software (Molecular Devices, LLC, Sunnyvale, CA, USA),
color thresholds were defined for the entire tumor area
and the specific antibody bound tissue only. Percent of
Figure 1 Caki-1 tumor growth curves over 40 days. Data from all
mice are included; mouse numbers are shown in brackets. Sunitinib
(40 mg/kg/day) treatment started on day 13 and finished on day 31.
Data are shown as mean ± SEM. **p < 0.01; n.s., not significant.
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pixels for each of the investigated factors.
In vitro cell uptake
The human renal cell carcinoma cell line, Caki-1 (American
Tissue Cell Culture (ATCC)), and for comparison, the
human mammary carcinoma cell line MCF-7 (a gift from
Dr. David Murray, Cross Cancer Institute, University of
Alberta) were used. The cell lines were cultured at 37°C
and 5% CO2 (standard conditions) in F-12/DMEM medium
supplemented with 10% fetal bovine serum, 2 mM glu-
tamine, 1% penicillin/streptomycin, 10 mM HEPES, 1 mM
sodium pyruvate, and 1% non-essential amino acids. Using
glass cell culture dishes with a diameter of 55 mm, the
cells were plated at a density of approximately 500,000
cells per plate and incubated for 48 h under normal condi-
tions at 37°C and 5% CO2. Following that time, half of the
plates were taken for culturing the cells under hypoxic
conditions over the next 24 h; the others were kept
under normal cell culture conditions. Hypoxic cell culture
conditions were achieved using a special sealed vacuum
chamber device (Division of Experimental Oncology,
Department of Oncology, University of Alberta) in which
O2 was almost entirely replaced with N2 (O2 < 0.1%) [42].
For the radiotracer incubation, the medium was replaced
with Krebs-Ringer buffer (115 mM NaCl, 5.9 mM KCl,
1.2 mM MgCl2, 1.2 mM NaH2PO4, 1.2 mM Na2SO4,
2.5 mM CaCl2, 25 mM NaHCO3, and 5 mM glucose at a
pH of 7.4) at room temperature. Around 2.5 to 3.5 MBq
of [18F]FAZA, containing buffer was added per plate and
incubated for 4 h under either normal or hypoxic condi-
tions. Sunitinib maleate 90 μL of 10−4 M (in DMSO) was
added to selected plates to analyze the effect of sunitinib
on cellular [18F]FAZA binding. After incubation, the cells
were rinsed three times with ice-cold Krebs-Ringer buffer
to stop further cell uptake and then immediately lysed
using 1 mL 5% trichloroacetic acid (TCA) for 1 h. One
plate of each condition was used for protein quantification
using the BCA protein assay kit (Pierce, Rockford, IL,
USA) according to the manufacturer's recommendations,
and bovine serum albumin was used as the protein stand-
ard. Following the 1-h lysis with TCA, the supernatants
were collected and placed into scintillation vials to be
counted using the Wizard gamma counter (Wallac 1480
Wizard-3, Perkin-Elmer) in order to determine radioactiv-
ity uptake levels in the cells. Radiotracer cell uptake levels
were normalized to percent of the total added radioactivity
per milligram protein (% radioactivity/mg protein). Data
are presented as means ± SEM.
Results
Effect of sunitinib on Caki-1 tumor growth
Figure 1 summarizes the Caki-1 tumor growth over a
40-day period based on all mice used for the long-termtherapy protocol with additional therapy withdrawal. The
tumors were allowed to grow for 13 days until therapy
with sunitinib was started. After therapy was started on
day 13, tumor growth in the treatment group decreased
over the next 2 weeks. After therapy, withdrawal tumor
growth rates still differed; however, at the end of the study
at day 40, the tumor sizes between both groups were com-
parable again, indicating an increased tumor growth rate
in the treated group (tumor growth flare).
Characterization of the Caki-1 tumor model with
[18F]FAZA
Prior to determining the effects of a sunitinib therapy on
Caki-1 tumor's oxygenation, the hypoxia tracer [18F]
FAZA was used to evaluate the basic hypoxia character-
istics of this preclinical RCC model. Figure 2 shows se-
lected PET images at 30 min and 2 and 3 h p.i. from 3-h
dynamic acquisitions. The generated TACs for the up-
take profile of [18F]FAZA in tumor and muscle tissue, as
well as the subsequent tumor/muscle ratios over 3 h, are
shown at the bottom of Figure 2. The TACs revealed a
rapid uptake of [18F]FAZA into the tumor tissue and re-
sulted in an SUVmean of 0.35 ± 0.03 after 1 h p.i. and an
almost unchanged SUVmean of 0.32 ± 0.02; n = 6 tumors/
three mice after 3 h p.i. The overall [18F]FAZA uptake
into the Caki-1 tumor cells seemed to be very low, indi-
cating lower levels of hypoxia. However, [18F]FAZA also
cleared from the muscle tissue over time (SUVmean,3h,
0.23 ± 0.04; n = 6/3), leading to an increased tumor/
muscle ratio over time from 1.10 ± 0.03 at 1 p.i. to 1.56 ±
0.12 (n = 6) after 3 h p.i. This analysis confirmed that
after 3 h p.i., the subcutaneous Caki-1 model may pos-
sess an optimal tumor/background ratio sufficient for static
PET image analysis.
Figure 2 Dynamic [18F]FAZA images in a BALB/c nude mouse bearing two Caki-1 tumors. Time-activity curves for the radioactivity uptake
into Caki-1 tumor and muscle tissue as well as the tumor/muscle ratios (bottom). Image data are presented as maximum intensity projections
(MIP) at 30 min, 2 and 3 h post injection. Data in TACs as SUV and mean ± SEM from six tumors out of three mice and three regions of muscle
from those three mice.
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Following the characterization of the Caki-1 RCC model,
[18F]FAZA PET was used to detect the effects of sunitinib
on the tumor's hypoxia. Five days of sunitinib (intraperi-
tonial injection) led to a decrease in [18F]FAZA tumor
uptake (Figure 3). As dynamic PET experiments revealed,
lower levels of radiotracer were detected and these
decreased over the 3-h time frame. In treated animals,
[18F]FAZA uptake into the Caki-1 tumors reached its
maximum at 30 min p.i. (SUVmean of 0.38 ± 0.02 (n = 4/2))
and decreased to a final SUVmean,3h of 0.23 ± 0.02 (n = 4/2;
p < 0.05). In control tumors, a SUVmean of 0.44 ± 0.05 was
measured after 60 min and 0.42 ± 0.05 (n = 4 tumors/two
mice) after 3 h p.i. This observation showed clearance of
[18F]FAZA and therefore less trapping of the radiotracer,
indicative for a lower level of hypoxia in the treated versus
the non-treated tumors. Biodistribution analysis of tumor
tissue after the PET experiments confirmed these findings:
2.20 ± 0.30% ID/g in the controls versus 1.38 ± 0.13% ID/g
(n = 8/4; p < 0.05) in the sunitinib-treated tumors.
Uptake and retention of [18F]FAZA in Caki-1 tumors
was further analyzed by kinetic modeling using a two-
compartment model [41]. All four kinetic parameters
k1 to k4 were calculated for control as well as for the
sunitinib-treated tumors (Figure 3, bottom right). In the
presence of sunitinib, all constants were found to be in-
creased, significantly even for k2 and k4 with a p < 0.05.
Once diffused into the cell, [18F]FAZA either diffuses back
out of the cell or is reduced for further intracellularbinding. The first process is governed by the rate constant
k2 and is elevated under sunitinib therapy, as is the latter,
which is governed by k3. The ratio k3/(k2 + k3), however,
remains unchanged, indicating that once it has crossed
the cell membrane, a similar fraction of [18F]FAZA will be
further reduced in the presence or absence of sunitinib.
Once reduced, re-oxygenation of [18F]FAZA is governed
by the rate constant k4. It is amplified in the presence of
sunitinib, resulting in the observed reduction in uptake
under treatment (Figure 3). Analysis of the fractional
blood volume (fbv) revealed similar values in the absence
and presence of sunitinib: 0.160 ± 0.032 and 0.148 ± 0.036
(n = 4), respectively, indicating similar overall perfusion of
the tumor volume (yet not necessarily the microenviron-
ment, which can display hypoxia).
Following PET imaging and biodistribution experiments,
tumor tissue slices were analyzed immunohistochemically.
Figure 4 summarizes the results for pimonidazole, CD-31,
VWF, and Ki67 staining. Treatment of Caki-1 tumor-
bearing mice with sunitinib led to reduced staining of
Ki67, CD-31, and an increase in VWF. Although no signifi-
cant difference in the quantification of the pimonidazole
staining was detectable, a qualitative trend of decreased
staining density was observed in the long-term study
(see Figure 5). A potential reason for this observation
could be that animals were sacrificed at 1 h p.i. of pimoni-
dazole for the short-term experiments. Since pimonidazole,
like FAZA, is a 2-nitromidazole, no effects of sunitinib were
detected after 1 h p.i. in accordance with the PET results
(Figure 3). A 1.83 ± 0.10% CD-31 binding was determined
Figure 3 [18F]FAZA images in Caki-1 tumor mice in the absence (left) and presence (right) of sunitinib. The insets show the respective
transaxial slides of both mice. Time-activity curves for the radioactivity uptake into Caki-1 tumor in the absence and presence of sunitinib in vivo
(bottom left). Image data are shown as maximum intensity projection (MIP) at 3 h post injection and TAC data as SUV and mean ± SEM from four
tumors grown in two mice. Kinetic constants k1 to k4 were calculated based on a two-compartment model (bottom right). Changes were significant
for k2 and k4 (*p < 0.05).
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samples from sunitinib-treated animals showed reduced
binding of 0.58 ± 0.05% CD-31 (n = 8/4 - tumors from four
mice; p < 0.001). Additionally, in the controls, 0.53 ± 0.05%
VWF positive cells were found versus 0.31 ± 0.08% in
sunitinib-treated samples (n = 8/4; p < 0.001). Ki67 immu-
nohistochemistry showed a decreased binding from 75 ±
2% Ki67 positive cells in the controls to 54 ± 6% Ki67 posi-
tive cells in the treated samples (n = 8/4; p < 0.001).
Monitoring therapy effects and withdrawal of sunitinib
with [18F]FAZA
Following the investigation of short-term effects of suniti-
nib on tumor oxygenation, a second experimental series
was performed in order to analyze the longitudinal effects
of anti-angiogenic therapy on Caki-1 tumor oxygenation.
Figure 5 summarizes the PET results with [18F]FAZA for
the effect of sunitinib during the therapy and after therapy
withdrawal. Treated Caki-1 tumors clearly showed higher
radioactivity uptake levels than the control tumors, con-
firming that in the presence of sunitinib, the amount of
tumor hypoxia is decreased in the tumor microenviron-
ment. After 9 days of sunitinib therapy (Figure 5, left), the
SUVmean,3h of control tumors was found to be 0.24 ± 0.02,
while the SUVmean,3h of sunitinib-treated tumors was
0.19 ± 0.01 (n = 8; p < 0.05). Similar results were obtainedwhen analyzing SUVmax values, which are more relevant
for clinical use: 0.38 ± 0.03 (control) versus 0.29 ± 0.02
(9 days of sunitinib; n = 8, p < 0.05). Pimonidazole staining
from tissue slices confirmed a reduction in hypoxia of the
treated tumors. Twelve days after sunitinib therapy was
withdrawn, [18F]FAZA uptake into the treated tumors in-
creased again, leading now to even higher uptake levels
than the control tumors (Figure 5, right): SUVmean, 3 h of
0.18 ± 0.01 (control) versus 0.23 ± 0.01 (sunitinib-treated;
n = 6, p < 0.05). Analysis of SUVmax revealed the following
values: 0.30 ± 0.02 (control) versus 0.36 ± 0.02 (after ther-
apy withdrawal; n = 6, p < 0.05). This was indicative of
higher levels of hypoxia and corresponded to a flare effect
after withdrawal of sunitinib. The pimonidazole staining
confirmed this phenomenon with similar levels of binding
in both the control and the treated groups.
In vitro cell uptake
In order to assess the overall functional effects of a suni-
tinib treatment in vivo, uptake of [18F]FAZA into the
Caki-1 cells was analyzed directly in the absence and
presence of sunitinib in vitro. Hypoxia selective uptake
and retention (= trapping) of [18F]FAZA occurs only under
hypoxic conditions. After a 4-h incubation time, [18F]FAZA
uptake was significantly higher in the Caki-1 cells (Figure 6):
2.42 ± 0.09% (hypoxia) versus 0.24 ± 0.02% radioactivity/
Figure 4 Immunohistochemical staining with pimonidazole HCl, CD-31, Ki-67, and VWF in Caki-1 tumor tissue slices. Slices are shown
from control animals and mice treated with sunitinib (40 mg/kg/day) for 5 days (top). Quantified staining data for the percent positive stained
tissue. Data as mean ± SEM with **p < 0.01; ***p < 0.001 and n.s. for not significant.
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and proof of the experimental setup, MCF-7 cells, known
to have a higher uptake of the hypoxia PET tracer under
hypoxic conditions, were also analyzed: 2.63 ± 0.44% (hyp-
oxia) versus 0.37 ± 0.06% radioactivity/mg protein (n = 9;
p < 0.001; normoxia). Cellular trapping of [18F]FAZA into
the Caki-1 and MCF-7 cells was increased approxi-
mately eightfold to tenfold under hypoxic conditions,
confirming increased cellular retention of [18F]FAZA underFigure 5 Static [18F]FAZA images in BALB/c nude mice bearing two C
maximum intensity projection (MIP) at 3 h post injection. Top left: control m
control mouse versus a sunitinib-treated mouse which had received 13 day
Bottom: semi-quantified PET data as SUV in comparison to percent pimoni
tumors grown in x mice. *p < 0.05.hypoxic conditions. The presence of sunitinib (3 μM) did
not change the uptake properties of [18F]FAZA into the
cell lines (Figure 6), indicating no direct effect occurring
from this compound on the cellular uptake of a hypoxic
radiotracer.
Discussion
Four main findings of the current study may be summa-
rized as follows: (i) xenograft Caki-1 RCC tumors showaki-1 tumors on each upper flank. Image data are presented as
ouse versus sunitinib-treated mouse (9 days 40 mg/kg). Top right:
s of drug therapy followed by 12 days after therapy was finished.
dazole binding in tumor slices. Data as mean ± SEM from n analyzed
Figure 6 Uptake of [18F]FAZA into Caki-1 (renal cell carcinoma)
and MCF-7 cells (human breast cancer cell line). Cell uptake was
normalized to percent radioactivity per milligram protein, and data
are shown as mean ± SEM from n analyzed cell culture dishes from
x number of experiments. Cell uptake was measured under normoxic
and hypoxic conditions and in the presence and absence of
3 μM sunitinib.
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(ii) sunitinib therapy reduces [18F]FAZA tumor uptake,
indicating reduced tumor hypoxia; (iii) TKI withdrawal
flare phenomenon was observed after sunitinib was dis-
continued, resulting in a once more increased tumor
hypoxia; and (iv) sunitinib did not influence the direct
cellular uptake and retention of [18F]FAZA in the Caki-1
and MCF-7 cells under normoxic or hypoxic conditions
in vitro.
Currently, treatment of metastatic RCC with the TKI
sunitinib is recommended as one of the first therapy op-
tions [7,15,16]. Sunitinib causes reduced tumor size or
growth rate. In the current study, smaller Caki-1 tumor
sizes were observed in the treated mice. Meta-analysis of
metastatic RCC studies has shown that higher exposure
to sunitinib is correlated with improved treatment out-
comes. Patients with the highest exposure to sunitinib had
longer times to progression, and the probability of de-
creases in tumor size or of halting tumor growth was
higher in patients with the highest exposure to sunitinib
[16,43]. However, after therapy, Caki-1 tumors reached
similar sizes again, indicating that the tumors regained
their molecular characteristics which are essential for
tumor development and growth. Changes occurring during
therapy with sunitinib seem to be reversed after treatment
disruption, leading to further tumor progression. The goal
in patients would be to have a maximum exposure time tosunitinib which is associated with longer time to tumor
progression, longer overall survival, and greater decrease in
tumor size [43].
Therapy of metastatic RCC with TKIs can be monitored
with non-invasive imaging methods to analyze therapy
success as well as predict patient outcomes [22,23]. Sev-
eral preclinical and clinical studies have been carried out
to analyze therapeutic effects of a TKI such as sunitinib
or sorafenib utilizing PET [31-38]. Besides monitoring
tumor metabolism in RCC with [18F]FDG, [18F]FMISO
was used to analyze effects on tumor oxygenation status
and [18F]FLT for determination of proliferation. Dur-
ing the present study, [18F]FAZA was used. Although
[18F]FAZA in comparison to [18F]FMISO may exhibit
a better clearance pattern from non-targeting muscle tis-
sue based on its lower lipophylicity, there is still a debate
about the radiotracer of choice for imaging tumor hypoxia
[26-28]. In Caki-1 tumors, [18F]FAZA uptake amounted
to 1.5% to 2.2% ID/g after 3 h p.i. As analyzed from the
dynamic PET studies, initial uptake reached a maximum
level after approximately 40 to 60 min which did not fur-
ther increase. Image contrast with [18F]FAZA is achieved
based on the non-target tissue clearance over time. In
Caki-1 tumors, a tumor-to-muscle ratio of approximately
1.5 was reached after 3 h p.i.. The current findings are
in line with observations in other murine and human
xenograft models of different origin, where 1.3% to 3% ID/
g or even lower levels were measured at the same time p.i.
[26,27,44]. Similar to the Caki-1 model, low uptake of
[18F]FMISO was found in A498, another human RCC
xenografted tumor model [33].
PET is an ideal non-invasive imaging tool to use for
monitoring response to therapy. However, there are still
ongoing discussions of how patients would benefit from
monitoring tumor hypoxia status and how hypoxia-
directed therapy approaches could be used clinically
[30,45]. During the present study, sunitinib therapy led
to a reduction of tumor hypoxia levels by 22% to 46% as
determined with [18F]FAZA. Although sunitinib mainly
targets tumor vasculature and function, it can be con-
cluded that it also leads to a reduction of tumor hypoxia.
As Verwer et al. [41] have proposed, a reversible two-
tissue compartment model best describes uptake through
passive diffusion and initial retention based on a chemical
reduction of a nitroimidazole such as [18F]FAZA. Both
steps are reversible: higher oxygen levels can re-oxygenate
the reduced radiotracer, and [18F]FAZA may leave cells
again via diffusion into the plasma. Kinetic analysis of the
present dynamic data revealed that k1 to k4 were all ele-
vated in the presence of sunitinib, k2 and k4 even signifi-
cantly. Increased k1 shows that sunitinib-treated tumors
allow even faster cellular uptake of [18F]FAZA. Delivery of
the radiotracer through the tumor vasculature is rather
improved and not impaired. On the other hand, elevated
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for treated mice. One can conclude that in this case, more
re-oxygenated [18F]FAZA is present in the intracellular
compartment. The intracellular presence or absence of
[18F]FAZA is determined in this work to be due chiefly to
the difference in k4, i.e., the re-oxygenation of the reduced
[18F]FAZA, which is significantly elevated under sunitinib
therapy. The perfused percentage of each tumor, as deter-
mined by the fbv, was found to be equal (within error
margins) in each case, meaning that delivery of the radio-
tracer through the blood vessels is not impaired under su-
nitinib therapy. In summary, sunitinib treatment leads to
decreased uptake in tumor cells due to increased re-
oxygenation and back diffusion of [18F]FAZA caused by
overall lower hypoxia levels.
Congruent with the current findings, sunitinib also re-
duces [18F]FMISO uptake by 22% to 35% in metastatic
RCC patients [32]. The EGFR-blocker gefitinib showed
even higher inhibition of [18F]FAZA uptake (60% to 70%)
in xenograft A431 human squamous cell carcinoma [37].
Similar observations with [18F]FAZA and [18F]FMISO
were described in A431 tumor-bearing mice under ther-
apy with CI-1033, a pan-Erb-B inhibitor [46]. Studies with
[18F]FDG analyzing glucose metabolism revealed 17% to
75% reduction in uptake during a sunitinib therapy
[34-36], although with high variability for basic [18F]FDG
levels in RCC patients [47,48], reducing its utility in the
clinics. In addition, the proliferation marker [18F]FLT also
showed a 16% reduced uptake in RCC patients in the
presence of sunitinib [38]. Taken together, this supports
the conclusion that systemic therapy with the TKI suniti-
nib achieves therapeutic efficacy by decreasing tumor hyp-
oxia, metabolism, and proliferation. Monitoring of tumor
oxygen levels is feasible in lesions with a well-defined
population of hypoxic cells. This allows detection of re-
duced hypoxia during sunitinib therapy, while non-
hypoxic metastases would not be expected to change [32].
Immunostaining with pimonidazole did only show a
tendency for decreased binding to hypoxic cells in the
short-term study. This may be explained by the short in-
cubation time of only 1 h compared to 3 h in the long-
term study. As the dynamic PET study reveals, effects of
sunitinib on [18F]FAZA are likewise not detectable at 1
h p.i. In theory, pimonidazole should behave similarly to
[18F]FAZA since both are 2-nitroimidazoles. Pimonida-
zole binding was reduced after 3 h p.i. by 30% which is
similar to the 21% reduction of [18F]FAZA. Considering
the small numbers of animals, n, and thus relatively large
SEM, this difference was insignificant. Immunohistochem-
istry with CD-31 and Ki67 resulted in a reduction in endo-
thelial cells (and therefore mean vessel density and cell
proliferation), pointing to a decrease in oxygen consump-
tion and demand. This may have contributed to improved
oxygenation of the sunitinib-treated Caki-1 tumors whichcorrelates well with the fact that [18F]FAZA delivery to the
tumor cells was not impaired under sunitinib. From a clin-
ical perspective, improved oxygenation has been shown to
improve response to conventional chemotherapy, and
radiotherapy, as well as reduce metastatic potential [49].
While sunitinib therapy leads to a pronounced reduc-
tion in tumor hypoxia, termination of therapy resulted in
an increased hypoxia with even higher levels of [18F]FAZA
uptake compared to the control tumors. Following the re-
lease of TK inhibition, the tumor cell activity rebounds
and experiences accelerated proliferation. This withdrawal
flare phenomenon has not been thoroughly investigated
subsequent to discontinuation of anti-angiogenic therapy.
Similar rebound effects were observed in human renal cell
cancer, where the SUV of [18F]FLT increased by 15% after
sunitinib withdrawal [38]. Currently, patients receive suni-
tinib in an on-and-off regimen [50]. Following treatment
discontinuation, patients sometimes experience recurrent
pain in metastatic sites, as a result of flare re-growth. It
has been proposed that during this period of withdrawal,
tumor cells are stuck in the ‘S’ phase and therefore are
more vulnerable to combination cytotoxic chemotherapy
[38]. This may be a useful strategy for therapy monitoring
of RCC with PET, e.g., determining the hypoxia status.
Since direct effects of sunitinib on [18F]FAZA uptake
into the Caki-1 cells can be excluded from the in vitro
studies, the observed reduction in tumor hypoxia in vivo
must be related to other effects of sunitinib. Sunitinib was
originally designed to specifically inhibit VEGFR, PDGFR,
and C-kit; however, it has been found to inhibit other
types of kinases as well, including non-receptor tyrosine
kinases, receptor tyrosine kinases, tyrosine kinase-like ki-
nases, cyclin-dependant kinases, and mitogen-activated
protein kinase [11]. For this reason, it is reasonable to
assume that sunitinib, as a type I TKI, has a greater
number of off-target effects compared to some of the
more specific TKIs categorized as type II, such as so-
rafenib and imatinib. This may help explain some con-
trasting effects observed in different cell lines following
TKI therapy [33,47,51–53].
Conclusion
The present results show that [18F]FAZA PET could be
used to detect functional changes in the hypoxia status
of renal cell carcinoma. It was found that during therapy
with the TKI sunitinib, [18F]FAZA uptake and trapping
in Caki-1 tumors was reduced, indicating improved
tumor oxygenation. Upon withdrawal of sunitinib therapy,
[18F]FAZA uptake into the tumor cells again increased,
demonstrating a rebound in tumor hypoxia to even
higher levels. This work demonstrates that [18F]FAZA
PET could be used to monitor TKI therapy clinically and
may guide combination therapies dependent on tumor
hypoxia status.
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